Chemistry: analytical and immunological testing – Biological cellular material tested
Patent
1995-12-01
1998-11-17
Ivy, C. Warren
Chemistry: analytical and immunological testing
Biological cellular material tested
514886, G01N 3348
Patent
active
058375481
ABSTRACT:
The present invention provides a method for treating a lipid body-mediated condition, such as inflammation or cancer, in an vertebrate by administering to the vertebrate a sufficient amount of an agent which inhibits the formation of lipid bodies in cells involved in inflammation. The agent can inhibit lipid body formation by inhibiting any biological activity necessary for lipid body formation.
Another embodiment of the present invention is a method or assay for assessing the ability of a compound to inhibit lipid body formation in cells in vitro. The method comprises the steps of priming the cells for lipid body formation, contacting the cells with the compound under study, and comparing lipid body numbers in the cells with lipid body numbers in primed cells not contacted with the compound of interest. This method can be automated, yielding an efficient high-throughput assay for the efficient and rapid screening of large numbers of potential anti-inflammatory drugs.
REFERENCES:
patent: 5409710 (1995-04-01), Leonard
patent: 5449679 (1995-09-01), Leonard
Vane, J., "Toward a better aspirin," Nature 367: 215-216 (1994).
Langenbach, R., et al., "Prostaglandin Synthase 1 Gene Disruption in Mice Reduces A rachidonic Acid-Inducing Inflammation and Indomethacin-Induced Gastric Ulceration," Cell, 483-492 (1995).
Morham, S. G., et al., "Prostaglandin Synthase 2 Gene Disruption Causes Severe Renal Pathology in the Mouse," Cell 83: 473-482 (1995).
Weller, P. F. et al., "Cytoplasmic Lipid Bodies of Human Eosinophils," Am. J. of Pathology, 138(1) : 131-148 (1991).
Dvorak, A.M., et al., "Ultrastructural Immunogold Localization of Prostaglandin Endoperoxide Synthase (Cylooxygenase) to Non-membrand-bound Cytroplasmic Lipid Bodies in Human Lung Mast Cells, Alveolar Macrophages, Type II Pneumocytes, and Neutrophils," The J. of Histochemistry and Cytochemistry, 40(6) : 759-769 (1992).
Dvorak, A. M., et al., "Prostaglandin Endoperoxide Synthase (Cyclooxygenase) : Ultrastructural Localization to Nonmembrane-Bound Cytoplasmic Lipid Bodies in Human Eosinophils and 3T3 Fibroblasts," Int Arch Allergy Immunol, 105: 245-250 (1994).
Dvorak, A. M., et al., "Human Lung Mast Cell and Alveolar Macrophage Cytoplasmic Lipid Bodies contain Arachidonic Acid and Prostaglandin Endoperoxide Synthase (Cyclooxygenase), the Substrate and Enzyme Necessary for Prostaglandin Production," Int Arch Allergy Immunol, 99: 208-217 (1992).
Dvorak, A. M. et al., "Ultrastructural Localization of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) to Isolated, Purified Fractions of Guinea Pig Periotoneal Macrophage and Line 10 Hepatocarcinoma Cell Lipid Bodies," Int Arch Allergy Immunol, 191: 136-142 (1993).
Beil, W. J., et al., "Ultrastructural immunogold localization of subcellular sites of TNF-.alpha. in colonic Crohn'disease," J. of Leukocyte Biology, 58: 284-298 (1995).
Weller, P. F., and Dvorak, A. M., "Lipid bodies: Intracellular site for eicosanoid formation," J. Allergy Clin Immunol., 94(64) (Part 2): 1151-1156 (1994).
Vane, J.R., "Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs", Nature 231: 232-235 (1971).
Weller, R.F., et al., "Cytoplasmic Lipid Bodies of Human Neutrophilic Leukocytes", Am. J. Pathology, 135(5): 947-959 (1989).
Weller, P.F., and Dvorak, A.M., "Arachidonic Acid Incorporation by Cytoplasmic Lipid Bodies of Human Eosinophils", Blood, 65(5): 1269-1274 (1985).
Dvorak, A.M., et al., "Lipid Bodies: Cytoplasmic Organelles Important to Arachidonate Metabolism in Macrophages and Mast Cells," J. Immunology, 131(6): 2965-2976 (1983).
Weller, P. F., et al., "Cytoplasmic Lipid Bodies of Neutrophils: Formation Induced by cis-Unsaturated Fatty Acids and Mediated by Protein Kinase C," J. Cell Biol., 113(1): 137-146 (1991).
Sigal, E., "The Molecular Biology of Mammalian Arachidonic Acid Metabolism," Am J. Physiol, 260: L13-L28 (1991).
Laposata, M., et al., "Icosanoid Production Can Be Decreased without Alterations in Cellular Arachidonate Content or Enzyme Activities Required for Arachidonate Release and Isosanoid Synthesis," J. Biol. Chem, 263(7): 3266-3273 (1988).
Giovannucci, E., et al., "Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professional", Annals Intern Medicine, 121(4): 241-246 (1994).
Thun, M. J., et al., "Asprin Use and Risk of Fatal Cancer," Cancer Res., 53: 1322-1327 (1993).
Greenberg, E. R., et al., "Reduced Risk of Large-Bowel Adenomas Among Asprin Users," J. Nat. Cancer Inst, 85(11): 912-916 (1993).
Nissen, H, M., "On Lipid Droplets in Renal Interstitial Cells, II. A Histological Study on the Number of Droplets in Salt Depletion and Acute Salt Repletion", Zeitschrift fur Zellforsehung 85:483-491 (1968).
Bozza, P. T. et al., "Mechanisms of Platelet-activating Factor-inducing Lipid Body Formation: Requisite Roles for 5-Lipoxygenase and De Novo Protein Synthesis in the Compartmentalization of Neutrophil Lipids", J. Exp. Med, The Rockefeller University Press, vol. 183: 1515-1525 (Apr. 1996).
Hexeberg, S. et al., "Docosahexaenoic acid induces lipid accumulation in myocardial cells of rats", Scand J. Clin Lab Invest, 54: 665-671 (1994).
Weller, P. F. et al., "Cytoplasmic Lipid Bodies of Human Neutrophilic Leukocytes", Am. J. of Pathology 135(5): 947-959 (Nov. 1989).
Weller, P. F. et al., "Cytoplasmic Lipid Bodies of Human Eosinophils", Am. J. of Pathology, 138(1): 141-148 (Jan. 1991).
Bozza Patricia T.
Dvorak Ann M.
Weller Peter F.
Aulakh Charanjit S.
Beth Israel Hospital
Ivy C. Warren
LandOfFree
Treatment of inflammation by inhibition of lipid body formation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of inflammation by inhibition of lipid body formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of inflammation by inhibition of lipid body formation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-883712